Boyd B. Scott

2.4k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

Boyd B. Scott is a scholar working on Molecular Biology, Orthopedics and Sports Medicine and Oncology. According to data from OpenAlex, Boyd B. Scott has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Orthopedics and Sports Medicine and 9 papers in Oncology. Recurrent topics in Boyd B. Scott's work include Bone health and osteoporosis research (9 papers), Bone health and treatments (8 papers) and Bone Metabolism and Diseases (8 papers). Boyd B. Scott is often cited by papers focused on Bone health and osteoporosis research (9 papers), Bone health and treatments (8 papers) and Bone Metabolism and Diseases (8 papers). Boyd B. Scott collaborates with scholars based in United States, United Kingdom and Italy. Boyd B. Scott's co-authors include Subrata Ghosh, Stephen Middleton, Silvio Danese, Juan Ricardo Márquez, Remo Panaccione, Paul Rutgeerts, Hanzhe Zheng, Hubert J. F. van Hoogstraten, G R Barclay and Le T. Duong and has published in prestigious journals such as Gastroenterology, The Journal of Clinical Endocrinology & Metabolism and Journal of Bone and Mineral Research.

In The Last Decade

Boyd B. Scott

26 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

2013 685 citations Remo Panaccione, Subrata Ghosh et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Boyd B. Scott United States	16	648	552	541	411	336	26	1.5k
K. Lea Sewell United States	16	253 0.4×	125 0.2×	564 1.0×	415 1.0×	402 1.2×	31	1.9k
Sylvie Ferrari‐Lacraz Switzerland	20	149 0.2×	310 0.6×	352 0.7×	344 0.8×	72 0.2×	60	1.9k
Katsuhiko Hasumi Japan	27	195 0.3×	479 0.9×	387 0.7×	377 0.9×	66 0.2×	112	1.9k
Bernhard Meister Austria	22	108 0.2×	121 0.2×	542 1.0×	437 1.1×	56 0.2×	65	1.7k
James E. Wheeler United States	27	347 0.5×	145 0.3×	213 0.4×	392 1.0×	22 0.1×	61	2.2k
Joseph M. Baron United States	22	181 0.3×	174 0.3×	355 0.7×	175 0.4×	30 0.1×	72	1.8k
Melek Ergin Türkiye	21	76 0.1×	99 0.2×	510 0.9×	456 1.1×	64 0.2×	89	1.5k
João L. Ascensão United States	21	377 0.6×	173 0.3×	334 0.6×	529 1.3×	18 0.1×	65	1.8k
Elena E. Solomou Greece	18	188 0.3×	113 0.2×	351 0.6×	386 0.9×	43 0.1×	70	2.0k
Sara Galluzzo Italy	21	101 0.2×	64 0.1×	339 0.6×	605 1.5×	112 0.3×	42	1.5k

Countries citing papers authored by Boyd B. Scott

Since Specialization

Citations

This map shows the geographic impact of Boyd B. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boyd B. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boyd B. Scott more than expected).

Fields of papers citing papers by Boyd B. Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boyd B. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boyd B. Scott. The network helps show where Boyd B. Scott may publish in the future.

Co-authorship network of co-authors of Boyd B. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Boyd B. Scott. A scholar is included among the top collaborators of Boyd B. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boyd B. Scott. Boyd B. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saag, Kenneth G., Peter Alexandersen, Claude-Laurent Benhamou, et al.. (2016). Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT). Bone Abstracts. 1 indexed citations

Bonnick, Sydney Lou, Alberto Odio, Santiago Palacios, et al.. (2013). Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 98(12). 4727–4735. 47 indexed citations

Cabal, Antonio, Parker D. Mathers, Alan T. Savitz, et al.. (2013). High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone. 56(2). 497–505. 26 indexed citations

Panaccione, Remo, Subrata Ghosh, Stephen Middleton, et al.. (2013). Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis. Gastroenterology. 146(2). 392–400.e3. 685 indexed citations breakdown →

Chapurlat, Roland, Sydney Lou Bonnick, Alberto Odio, et al.. (2013). Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate- a randomized placebo-controlled trial. Bone Abstracts. 1 indexed citations

Cabal, Antonio, Andres Laib, Boyd B. Scott, et al.. (2012). Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: A study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone. 50(6). 1379–1388. 22 indexed citations

Frenkl, Tara L., Radha Railkar, Neal D. Shore, et al.. (2011). Evaluation of an experimental urodynamic platform to identify treatment effects: A randomized, placebo‐controlled, crossover study in patients with overactive bladder. Neurourology and Urodynamics. 31(1). 69–74. 3 indexed citations

Frenkl, Tara L., Radha Railkar, John Palcza, et al.. (2011). Variability of urodynamic parameters in patients with overactive bladder. Neurourology and Urodynamics. 30(8). 1565–1569. 12 indexed citations

Pennypacker, Brenda L, et al.. (2011). Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. Journal of Bone and Mineral Research. 27(3). 524–537. 108 indexed citations

10.

Chan, Siew Pheng, Boyd B. Scott, & Shuvayu S. Sen. (2010). An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: Physician and patient attitudes and beliefs. BMC Musculoskeletal Disorders. 11(1). 248–248. 15 indexed citations

11.

Traynor, Anne M., Glenn Liu, Keith T. Flaherty, et al.. (2010). Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(2). 305–314. 73 indexed citations

12.

Adunsky, Abraham, Julie Chandler, Norman Heyden, et al.. (2010). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics. 53(2). 183–189. 46 indexed citations

13.

Pennypacker, Brenda L, Le T. Duong, P. Masarachia, et al.. (2010). Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. Journal of Bone and Mineral Research. 26(2). 252–262. 84 indexed citations

14.

Wu, Zhongren, et al.. (2008). Purification and characterization of recombinant human renin for X-ray crystallization studies. BMC Biochemistry. 9(1). 19–19. 8 indexed citations

15.

Scott, Boyd B., Gerard M. McGeehan, & Richard K. Harrison. (2006). Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension. Current Protein and Peptide Science. 7(3). 241–254. 15 indexed citations

16.

Wu, Zhongren, et al.. (2004). Purification and characterization of recombinant human cathepsin E expressed in human kidney cell line 293. Protein Expression and Purification. 37(1). 53–60. 4 indexed citations

17.

Scott, Boyd B., Paola Zaratin, Geoffrey D Clarke, et al.. (2004). C20orf9-003 (ACI-1), a Gene Localized on Chromosome 20q13.12 Encoding for a 49 kD Cytoplasmic Protein with a Putative Nucleotide Binding Site. DNA sequence. 15(1). 1–8. 2 indexed citations

18.

Misiano, Paola, Boyd B. Scott, Mark A. Scheideler, & Martine Garnier. (2003). PTH2 receptor-mediated inhibitory effect of parathyroid hormone and TIP39 on cell proliferation. European Journal of Pharmacology. 468(3). 159–166. 7 indexed citations

19.

Scott, Boyd B. & C.G. Chapman. (1998). The putative 116 kDa osteoclast specific vacuolar proton pump subunit has ubiquitous tissue distribution. European Journal of Pharmacology. 346(1). R3–R4. 15 indexed citations

20.

Scott, Boyd B., et al.. (1997). Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis & Rheumatism. 40(3). 490–498. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact